Mironid, a Glasgow-based biopharmaceutical company developing a treatment for a rare kidney disease, has raised $46m (£34m) in Series B funding to advance the clinical development of its treatment. [1]
The company is developing small molecule therapeutics to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), a rare, life-threatening hereditary kidney disease, as well as the most common hereditary kidney disorder.
The firm’s first-in-class LoAc small molecules are the only drug class to directly target cyclic AMP (cAMP), which is active throughout the disease process. The company’s preclinical data indicates efficacy, as well as a favourable safety profile across the disease’s endpoints, being shown to reduce both cyst number and kidney volume.
The funding round was supported by new investor the Scottish National Investment Bank, joining existing investors Epidarex Capital, Sofinnova Partners, Roche Venture Fund, BioGeneration Ventures and the University of Strathclyde.
Neil Wilkie, CEO at Mironid, commented: “ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60.”
“Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases.”
[1]: Mironid raises £34m to advance treatment for rare kidney disease